Akili Interactive Labs and Pfizer are partnering to evaluate patients’ risk of developing Alzheimer’s disease by following their performance while playing a specialized video game, Akili announced Jan. 9.

Biopharmaceutical company Intellect Neurosciences announced Jan. 16 that a potentially disease-modifying tau agent is in the preliminary stages of validation for neurological diseases including Alzheimer’s.

A bill that would increase Alzheimer’s research funding appropriations by $122 million has passed Congress and is now under deliberation by the president.

German research center Helmholtz Zentrum Munchen announced today that the company had successfully finalized three new spin-offs within the past year to include SurgVision, Trianta Immunotherapies and Dosimetrics.

A new label-free molecular imaging system called the 3D nanoSIMS could provide superior drug research studies at intensely tiny spatial resolutions, announced the National Physical Laboratory in Middlesex, United Kingdom, on Dec. 10.

Average survival for metastatic melanoma patients is less than 5 percent after five years—a disheartening figure, but an investigational agent incorporating benzamide in a melanin-targeted SPECT radiotracer could change the numbers, according to a study published Nov. 16 in the Journal of Nuclear Medicine.

Two novel cardiovascular PET agents are in the wings from FluoroPharma Medical, according to a recent profile in Forbes magazine.

The usual subjects in the Alzheimer’s brain are patterns of beta-amyloid plaque and tau aggregation, but a third perpetrator, clusterin, may be playing a more important role in the development of the disease than previously thought, according to a study published Dec. 30 in JAMA Neurology.